8-K: Cue Biopharma's CUE-221 Shows Promising Phase 2 Results in CSU

Cue Biopharma announced positive topline results from its Phase 2 clinical trial of CUE-221 for Chronic Spontaneous Urticaria (CSU), demonstrating significant efficacy and a favorable safety profile.

Summary

• Cue Biopharma announced positive topline results from a Phase 2 clinical trial of CUE-221 in Chronic Spontaneous Urticaria (CSU).
• The trial, conducted in China with 145 participants, met its primary endpoint (HSS7=0 at week 12) and a key secondary endpoint (UAS7=0 at week 12) with statistical significance, particularly at the 4 mg/kg dose.
• CUE-221 demonstrated a dose-responsive effect, with the highest dose showing statistically significant results for complete response.
• The drug showed a favorable safety profile with no treatment-related serious adverse events or hypersensitivity reactions.
• Clinically meaningful benefit was maintained for up to 12 weeks off treatment at the 4 mg/kg dose.
• The company plans to initiate a Phase 2b/3 trial in CSU and a Phase 2 trial in food allergy, pending FDA review of data.

Sentiment

Score: 9

Explanation: StockSavvy.ai views this as a highly positive development, with strong clinical trial results indicating significant potential for CUE-221.

Positives

• Positive topline results from the Phase 2 clinical trial of CUE-221 in CSU.
• Primary endpoint (HSS7=0 at week 12) met with statistical significance across all dose levels.
• Key secondary endpoint (UAS7=0 at week 12) met statistical significance at the 4 mg/kg dose.
• Dose-responsive efficacy observed for CUE-221.
• Clinically meaningful benefit maintained for up to 12 weeks off treatment at the 4 mg/kg dose.
• Favorable safety profile with no treatment-related serious adverse events or hypersensitivity reactions.
• Evidence suggesting a fundamental biological difference and potential for a functional cure compared to existing therapies like omalizumab.
• Plans to advance CUE-221 into Phase 2b/3 trials for CSU and Phase 2 for food allergy.

Negatives

• While the primary endpoint was met at all dose levels, statistical significance for the key secondary endpoint was only achieved at the highest dose (4 mg/kg).
• Omalizumab was included as an active comparator but without planned statistical testing against it for the primary and secondary endpoints.
• The filing mentions a history of losses for the company in its forward-looking statements disclaimer.

Risks

• Potential setbacks in research and development efforts, including negative or inconclusive trial results.
• Serious and unexpected drug-related side effects or safety issues.
• Challenges associated with clinical trials conducted in China and the acceptability of data.
• Delays and changes in regulatory requirements and policies.
• Reliance on licensors, collaborators, and other business partners.
• Inability to obtain adequate financing for future operations.
• Competition from other therapies.
• General economic and market conditions.

Future Outlook

The company intends to initiate a Phase 2b/3 trial in CSU and a Phase 2 trial in food allergy, subject to FDA review of the sufficiency of the data from the Phase 2 CSU trial. The company also expects to present full clinical data from the Phase 2 CUE-221 trial at a future scientific meeting.

Management Comments

• "We are excited to share these positive results which we believe establish CUE-221 as a potential best therapeutic option for patients suffering with chronic spontaneous urticaria."
• "These findings reinforce our enthusiasm for the precision engineered, unique dual mechanism of action of CUE-221, reflecting science that is truly differentiated."
• "Based on the strength of these data, we are working toward the rapid initiation of a Phase 2b/3 study in CSU and continuing to advance a planned Phase 2 study in food allergy."
• "We thank the patients, investigators, and study staff, all of whom made these results possible."
• "We look forward to presenting the complete data set including PK and IgE analyses from this 36-week study at an upcoming scientific meeting."

Industry Context

StockSavvy.ai notes that the positive results for CUE-221 in CSU are significant, as CSU is a condition with many patients inadequately controlled by current standard treatments like H1 antihistamines. The potential for a differentiated mechanism of action, as suggested by the durable benefit and comparison to omalizumab, could position CUE-221 as a valuable new therapeutic option in the growing market for autoimmune and allergic diseases.

Comparison to Industry Standards

• The Phase 2 trial included omalizumab (XOLAIR) as an active comparator. CUE-221 at 4 mg/kg showed a higher rate of complete resolution of hives (54% vs 41%) and complete response (46% vs 29%) at week 12 compared to omalizumab.
• Post hoc analysis at Week 28 (12 weeks off-drug) showed a statistically significant difference favoring CUE-221 4 mg/kg versus omalizumab (36% delta for complete resolution of hives).
• The study design and endpoints (HSS7=0 and UAS7=0) are standard for evaluating CSU treatments.
• The observed reduction in UAS7 scores for CUE-221 at week 12 (e.g., -23% for 4mg/kg) is presented alongside data from other investigational therapies like Dupilumab, Remibrutinib, and RPT904, with CUE-221 showing a strong reduction in residual disease activity compared to placebo and competitive with other advanced therapies.

Stakeholder Impact

• Shareholders: Positive trial results are likely to be viewed favorably, potentially impacting stock price and investor confidence.
• Patients: The positive results suggest a potential new and more effective treatment option for individuals suffering from chronic spontaneous urticaria, offering hope for improved quality of life.
• Healthcare Providers: The data provides evidence for a new therapeutic approach that may offer advantages over existing treatments, influencing prescribing decisions.

Next Steps

• Host a conference call and live webcast to discuss clinical data on September 21, 2026.
• Initiate a Phase 2b/3 trial in CSU.
• Initiate a Phase 2 trial in food allergy.
• Present full clinical data from the Phase 2 CUE-221 trial at an upcoming scientific meeting.

Key Dates

Recommendation

The Phase 2 trial results for CUE-221 in CSU are exceptionally strong, meeting primary and key secondary endpoints with high statistical significance and demonstrating a durable benefit with a favorable safety profile. The potential for a differentiated mechanism of action and functional cure, coupled with plans for registration-enabling trials, suggests significant upside potential. This filing represents a major de-risking event and a strong positive catalyst for the company.

Keywords

CUE-221, Chronic Spontaneous Urticaria, CSU, Phase 2 Trial, Clinical Data, Biopharmaceutical, Immunological Disorders, IgE